-
April 29, 2019
Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Three
With: Mark Shapiro, PhDA Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. This is the final installment in a three-part series in which Dr. Shapiro has shared his thoughts on the question below. Read part 1 and part 2. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients… Read more »
-
April 22, 2019
Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Two
With: Mark Shapiro, PhDA Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. Last week, Dr. Shapiro shared his initial thoughts on the question below. Today, he discusses issues of cost and equitable access to care. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In… Read more »
-
April 15, 2019
Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part One
With: Mark Shapiro, PhDA Q&A with Mark Shapiro, PhD, Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In general, who pays the expenses of clinical trials? And, specifically, how are the costs for Right to Try and expanded-access approaches… Read more »
-
March 7, 2019
NCCN 2019 Annual Conference Includes Focus on Patient Experience with Innovative Therapies, Plus Updates on Biomarkers, Biosimilars, and the Latest Research on Cancer Care Bookmark
Emma Shtivelman, PhDExcerpt:
“More than 1,500 cancer care professionals are meeting in Orlando, Florida, March 21-23, for the NCCN 2019 Annual Conference, presented by the National Comprehensive Cancer Network® (NCCN®)—an alliance of 28 leading cancer centers. The conference offers more than 25 sessions presenting the latest treatment recommendations for lung, breast, prostate, colon, and other cancers, including new and emerging therapies. Other key topics include coordination of care, pain management during an opioid crisis, biosimilars, cancer-associated distress, biomarkers, genetic testing, and appropriate transition to end-of-life care. The keynote session highlights the benefits and challenges of treatment with new and innovative therapies (e.g. CAR T-cell) from the perspective of the patient and the clinicians caring for them.”
Go to full article published by the National Comprehensive Cancer Network on Mar 4, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
March 7, 2019
Structural and Clinical Barriers Keep 3 of 4 Cancer Patients from Participating in Trials Bookmark
Emma Shtivelman, PhDExcerpt:
“A new meta-analysis led by Dr. Joseph Unger of Fred Hutchinson Cancer Research Center has revealed that structural and clinical barriers prevent more than 3 out of 4 cancer patients from participating in clinical trials.
“The study is part of an ongoing effort to understand why patient participation is so low in cancer clinical trials. Unger, a health services researcher and biostatistician who focuses on disparities in cancer research, published his findings today in JNCI, the Journal of the National Cancer Institute.”
Go to full article published by Fred Hutch News Service on Feb 19, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
February 18, 2019
Capturing Patients’ Real-World Experiences to Improve Cancer Research and Care
With:A Q&A with Grace Castillo-Soyao, founder and CEO of Self Care Catalysts; grace@selfcarecatalysts.com Q: You are well known as a visionary in the field of Real World Experience-Evidence (RWEE). As the founder and CEO of Self Care Catalysts, headquartered in Toronto, how do you see RWEE evolving to favorably impact the field of oncology? A: I started Self Care Catalysts with some very basic… Read more »
-
February 11, 2019
The Crucial 90% Missed by Doctors on Computers
With: Kevin Knopf, MD, MPHA Q&A with Kevin B. Knopf MD, MPH, chairman of hematology and oncology at Highland Hospital in Oakland, California; kevinbknopf@gmail.com Q: A successful patient-physician relationship depends upon effective bidirectional attention and mutual understanding. Many patients and physicians believe that common current versions of mandated electronic health records (EHRs) severely impede that interaction, especially eye contact. How can a competent and caring clinical oncologist overcome… Read more »
-
February 4, 2019
Challenging Oncology Therapies With Moonshot Price Tags
With:A Q&A with Pramod John, PhD, CEO of VIVIO Health, a specialty drug management company in San Leandro, CA, that aims to provide better outcomes at lower costs; pramod@viviohealth.com Originally published December 13, 2017 Q: Some American pharmaceutical companies are well-known for pricing drugs at “whatever the market will bear.” In oncology, some specialty drugs seem to have price tags completely unrelated to the… Read more »
-
January 7, 2019
Yale Cancer Center Scientists Advise Caution in Immunotherapy Research Bookmark
Emma Shtivelman, PhDExcerpt:
“In a new study by Yale Cancer Center, scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets. The findings are published today in the journal Cell.
“Researchers around the world have been racing to create therapies that unleash the power of our immune systems against cancer. The most successful of these immunotherapies, which target a molecular pathway known as PD-1/PD-L1, have brightened the landscape for many people suffering with lung cancer and other types of tumors.”
Go to full article published by Yale Cancer Center on Dec 20, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 7, 2019
ASCO and Friends of Cancer Research Applaud NCI’s Expansion of Clinical Trial Eligibility Criteria Bookmark
Emma Shtivelman, PhDExcerpt:
“ASCO and Friends of Cancer Research (Friends) applaud the National Cancer Institute’s (NCI) recent revision of its clinical trial protocol template to broaden eligibility criteria for cancer clinical trials. The protocol template was expanded to help increase the opportunity for participation in NCI-funded clinical trials for patients with certain health-care conditions, as well as to provide an opportunity for patients younger than age 18 to participate in adult clinical trials in certain circumstances.”
Go to full article published by The ASCO Post on Dec 11, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.